{"nctId":"NCT00803595","briefTitle":"A Multinational Phase III Study of CS-8958 (MARVEL)","startDateStruct":{"date":"2008-11"},"conditions":["Influenza, Human"],"count":1002,"armGroups":[{"label":"CS-8958 Low Dose","type":"EXPERIMENTAL","interventionNames":["Drug: CS-8958"]},{"label":"CS-8958 High Dose","type":"EXPERIMENTAL","interventionNames":["Drug: CS-8958"]},{"label":"Oseltamivir phosphate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: oseltamivir phosphate"]}],"interventions":[{"name":"CS-8958","otherNames":[]},{"name":"CS-8958","otherNames":[]},{"name":"oseltamivir phosphate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of influenza\n* Axillary temperature of \\> or = to 37.5 degrees C\n\nExclusion Criteria:\n\n* Infection by bacteria species and/or virus other than influenza virus\n* Chronic respiratory disease\n* Renal dysfunction","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Alleviation of Influenza Illness","description":"The time to illness alleviation which was defined as the time from the initiation of trial treatment to the beginning of the first 21.5-h period in which all influenza symptoms were \"absent\" or \"mild.\" Patients recorded their severity of influenza symptoms (headache, myalgia/arthralgia, fatigue, chills/sweats, nasal symptom, sore throat, and cough) 4 times daily for 15 days. Patients whose influenza symptoms had not been alleviated at the time of their withdrawal from the study or at the end of the observation period were censored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.0","spread":null},{"groupId":"OG001","value":"85.8","spread":null},{"groupId":"OG002","value":"73.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time for Body Temperature to Return to Normal","description":"Time for return to normal axillary temperature was was defined as the time until the beginning of the first 21.5-hour period in which the axillary temperature returned to 36.9°C. Patients recorded their axillary temperature 4 times daily for 15 days. Patients whose axillary temperature had not been returned to 36.9°C at the time of their withdrawal from the study or at the end of the observation period were censored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.3","spread":null},{"groupId":"OG001","value":"58.0","spread":null},{"groupId":"OG002","value":"54.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":337},"commonTop":["Diarrhoea","Nasopharyngitis","Nausea","Alanine aminotransferase increase","Vomiting"]}}}